Sector: Health Care
Director information for GILEAD SCIENCES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Anthony Welters | Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care; Retired Senior Adviser to the Office of the CEO, UnitedHealth Group | 71 | ["Extensive experience in the health insurance and managed care industry", "Demonstrated commitment to delivering healthcare to underserved global communities", "leadership experience in health insurance", "managed care industry experience", "corporate governance experience", "experience with public company boards", "board leadership roles", "significant leadership experience on other public boards", "in-depth knowledge of Gilead", "extensive experience in the health insurance and managed care industry", "demonstrated commitment to delivering healthcare to underserved communities"] | ["Compensation and Talent Committee", "Nominating and Corporate Governance Committee"] | 2026 |
| Chairman and Chief Executive Officer | Chairman and Chief Executive Officer | ["30+ year career at Roche", "Bachelor\u2019s degree in biology from Georgetown University", "MBA from Columbia University", "Extensive knowledge and a deep understanding of the pharmaceutical industry", "Leadership positions and international business experience"] | ["Pharmaceutical Research and Manufacturers of America (PhRMA)", "Georgetown University"] | 2026 | |
| Daniel P. O’Day | Chairman of the Board, Chief Executive Officer, Gilead; Chairman and Chief Executive Officer | 61 | ["Significant leadership and international business experience in the pharmaceutical industry", "Deep understanding of the evolving global healthcare environment and demonstrated commitment to driving innovation across the business", "public, private and non-profit board experience", "track record of success in highly scientific and competitive therapeutic areas", "deep understanding of the evolving healthcare environment", "commitment to driving innovation", "unwavering commitment to driving innovation across all aspects of a business"] | [] | 2026 |
| Dietmar Berger, M.D., PH.D. | Chief Medical Officer | 63 | ["Board-certified internist, hematologist and oncologist", "More than 25 years of extensive experience in developing and delivering innovative medicines", "Prior Senior Vice President and Global Head of Development at Sanofi", "Led clinical development for various therapeutic areas at Sanofi", "Prior Executive Vice President and Global Head of Research & Development at Atara Biotherapeutics", "Development and medical affairs roles at Genentech, Bayer Healthcare Pharmaceuticals and Amgen", "Professor of Medicine at the University of Freiburg Hospital"] | [] | 2026 |
| Harish Manwani | Senior Operating Partner, Blackstone; Retired Chief Operating Officer, Unilever; Director; Chair | 72 | ["Strong leadership skills and broad global operational, sales and marketing and human resources expertise at a complex, multi-national company", "Experience in driving growth across complex organizations on a global scale"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Jacqueline K. Barton, Ph.D. | Professor Emerita, California Institute of Technology; Director | 73 | ["Extensive experience in chemistry and related fields, for which she has received many awards", "Accomplished academic and inventor who has performed pioneering medical research and discovery", "Business experience as a founder and leader of a molecular diagnostics company"] | ["Science Committee"] | 2026 |
| Javier J. Rodriguez | Chief Executive Officer, DaVita; Director | 55 | ["Significant leadership experience in the healthcare industry, including serving as chief executive officer and in various other executive roles of a Fortune 500 public healthcare company", "Recognized for his vision and leadership in transforming how kidney care is delivered and accelerating the digital transformation to improve patients\u2019 lives while lowering costs for the healthcare system", "Audit committee financial expert"] | ["Audit Committee"] | 2026 |
| Jeffrey A. Bluestone, Ph.D. | Former President and Chief Executive Officer, Sonoma Biotherapeutics; Director | 72 | ["Internationally-recognized leader in the field of immunotherapy and related fields, with a distinguished scientific and academic career spanning four decades", "Strong leadership experience in the healthcare industry"] | ["Science Committee"] | 2026 |
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer | 56 | ["Central to Gilead\u2019s portfolio diversification", "Orchestrated the historic launch of a novel, long-acting option for HIV prevention", "Led the rapid launch and global access efforts for Gilead\u2019s COVID-19 antiviral", "Champion of responsible, ethical use of artificial intelligence", "Passionate advocate for transformational healthcare", "Led successful U.S. launch of Yeztugo for HIV prevention", "Achieved >85% U.S. payer access ahead of schedule", "Secured partnerships with the Global Fund and U.S. State Department", "Oversaw Phase 3 clinical trials of Trodelvy"] | ["Arcus Biosciences", "Neurocrine Biosciences", "University of Southern California\u2019s Leonard D. Schaeffer Center for Health Policy and Economics"] | 2026 |
| John G. Kirkwood | Professor of Chemistry Emerita | ["John G. Kirkwood and Arthur A. Noyes Professor of Chemistry Emerita", "member of the faculty for more than 30 years", "Norman Davidson Leadership Chair of the division from 2009 to 2019", "Founder and board member of GeneOhm Sciences Inc.", "Member of Gilead\u2019s Scientific Advisory Board from 1989 to 2007", "Former director of both Dow Inc. and The Dow Chemical Company", "Former member of the board and Materials Advisory Committee of DowDupont Inc.", "Member of the National Academy of Sciences", "Member of the National Academy of Medicine", "Member of the American Philosophical Society", "Recipient of the 2010 National Medal of Science", "Recipient of the 2015 Priestley Medal"] | [] | 2026 | |
| Keeley M. Cain Wettan | Executive Vice President, General Counsel, Legal & Compliance | 52 | ["Responsible for overseeing the company\u2019s global legal and compliance functions", "Advises the Board of Directors and senior leadership on legal, regulatory, governance, risk and compliance matters", "Oversaw the company\u2019s litigation and investigations group", "Managed complex legal disputes and government investigations", "Played a key role in board and governance matters, mergers and acquisitions", "Practiced law at Simpson Thacher & Bartlett", "Earned bachelor's degree in political science from the University of Iowa", "Earned Juris Doctor from the University of California, Berkeley School of Law"] | ["Gilead Foundation"] | 2026 |
| Kelly A. Kramer | Retired Chief Financial Officer, Cisco Systems; Director; Chair | 58 | ["Significant financial expertise, including serving as chief financial officer of major companies or divisions in the technology and healthcare industries", "Experience in strategic and financial planning and corporate development", "Audit committee financial expert"] | ["Audit Committee"] | 2026 |
| Sandra J. Horning, M.D. | Retired Chief Medical Officer, Roche; Director; Chair | 77 | ["Significant leadership experience in the pharmaceutical and healthcare industry, including expertise in drug development in multiple therapeutic areas", "Physician with experience treating patients as a practicing oncologist"] | ["Nominating and Corporate Governance Committee", "Science Committee"] | 2026 |
| Scott Rosen | President and Chief Executive Officer | ["President and Chief Executive Officer at Sonoma Biotherapeutics, Inc.", "A.W. and Mary Margaret Clausen Distinguished Professor Emeritus", "Managing Director at Vie Ventures", "Published more than 500 papers on T-cell activation and immune tolerance", "Founding director of the Immune Tolerance Network", "Member of the National Academy of Sciences", "Member of the National Academy of Medicine", "Member of the American Academy of Arts and Sciences", "Recipient of a prestigious Guggenheim Fellowship", "Former Ludwig Professor and Director of the Ben May Institute at the University of Chicago", "Former director of Provention Bio, Inc."] | [] | 2026 | |
| Ted W. Love, M.D. | Former Chair of Board of Directors, Biotechnology Innovation Organization | 67 | ["Significant leadership experience in the biopharma industry, including serving as a chief executive officer of a global healthcare company", "Physician with a strong scientific background, known for championing access to care"] | ["Audit Committee"] | 2026 |
